

August 16, 2022 Sawai Pharmaceutical Co., Ltd.

Sawai Receives Approvals for Six Generic Drugs with 13 Strengths

Osaka, Japan – August 15, 2022 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Kenzo Sawai) received approvals by the Ministry of Health, Labour and Welfare for six generic drugs with 13 strengths. The four compounds marked with an asterisk below are approved for the first time as generics.

The list of approved products:

1. Esomeprazole Capsules, Granules for Suspension

Generic name:	Esomeprazole	Strengths:	Capsules: 10mg, 20mg
	Magnesium Hydrate*		Granules for Suspension: 10mg, 20mg
Brand products:	Nexium [®] Capsules 10mg	, 20mg, Nexium [®]	Granules for Suspension 10mg, 20mg

2. Escitalopram Tablets, OD Tablets

Generic name:	Escitalopram Oxalate*	Strengths:	Tablets: 10mg, 20mg
			OD Tablets: 10mg, 20mg
Brand products:	ts: Lexapro [®] Tablets 10mg, 20mg		

3. Ramelteon Tablets

Generic name:	Ramelteon	Strengths:	8mg
Brand products:	Rozerem [®] Tablets 8mg		

4. Tolvaptan OD Tablets

Generic name:	Tolvaptan	Strengths:	7.5mg, 15mg
Brand products:	Samsca [®] OD Tablets 7.5mg, 15mg		

5. Ibandronate Intravenous Injection Syringes

Generic name:	Ibandronate	Strengths:	1mg
	Sodium Hydrate*		
Brand products:	Bonviva [®] Syringes for Intravenous Injection 1mg		

6. Daptomycin for Intravenous Injection

Generic name:	Daptomycin*	Strengths:	350mg
Brand products:	Cubicin [®] IV 350mg		

The products announced in this press release are not approved by the Food & Drug Administration for sale and distribution in the United States.

♦ Contact Information ♦

Public Relations Office, Sawai Pharmaceutical Co., Ltd.

E-mail: koho@sawai.co.jp